Table 1.
Association of nuclear factor erythroid 2-like 3 expression with clinicopathological features of hepatocellular carcinoma patients in The Cancer Genome Atlas dataset n (%)
| Variable |
NFE2L3 expression |
Total cases | P-value | |
| Low (n = 172) | High (n = 172) | |||
| Tumor grade | 0.0006 | |||
| G1/2 | 122 (70.9) | 91 (52.9) | 213 | |
| G3/4 | 50 (29.1) | 81 (47.1) | 131 | |
| T stage | 0.0070 | |||
| T1 | 100 (58.1) | 71 (41.2) | 171 | |
| T2 | 35 (20.3) | 52 (30.2) | 87 | |
| T3/4 | 37 (21.5) | 49 (28.5) | 86 | |
| Pathologic stage | 0.0138 | |||
| I | 98 (57.0) | 71 (41.2) | 169 | |
| II | 35 (20.3) | 50 (29.1) | 85 | |
| III/IV | 39 (22.7) | 51 (29.7) | 90 | |
NFE2L3: Nuclear factor erythroid 2-like 3.